Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Prefabricated foot orthoses vs shoes Serious adverse events · children with symptomatic flat feet Foot orthoses for treating paediatric flat feet (2022) · Cochrane | no estimate extracted | NR | No studies |
Customised foot orthoses vs shoes Adverse events · children with asymptomatic flat feet Foot orthoses for treating paediatric flat feet (2022) · Cochrane | no estimate extracted | NR | No studies |
Customised foot orthoses vs shoes Serious adverse events · children with asymptomatic flat feet Foot orthoses for treating paediatric flat feet (2022) · Cochrane | no estimate extracted | NR | No studies |
Prefabricated foot orthoses vs shoes Function or disability · children with asymptomatic flat feet Foot orthoses for treating paediatric flat feet (2022) · Cochrane | no estimate extracted | NR | No studies |
Naldemedine vs placebo Laxation response: risk of spontaneous rescue‐free bowel movementsain the short termb · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving… (2022) · Cochrane | no estimate extracted | NR | No studies |
Naloxone vs placebo Laxation response: risk of spontaneous rescue‐free bowel movements in the short terma · people with cancer and receiving palliative care with opioid‐induced bowel dysfunction Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving… (2022) · Cochrane | no estimate extracted | NR | No studies |
Naloxone vs placebo Laxation response: risk of spontaneous rescue‐free bowel movements in the medium termb · people with cancer and receiving palliative care with opioid‐induced bowel dysfunction Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving… (2022) · Cochrane | no estimate extracted | NR | No studies |
Naloxone vs placebo Laxation response: patient assessment of change in bowel status at the end of trial · people with cancer and receiving palliative care with opioid‐induced bowel dysfunction Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving… (2022) · Cochrane | no estimate extracted | NR | No studies |
Naloxone vs placebo Adverse events · people with cancer and receiving palliative care with opioid‐induced bowel dysfunction Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving… (2022) · Cochrane | no estimate extracted | NR | No studies |
Naloxone + oxycodone prolonged release tablets vs oxycodone prolonged‐released tablets Laxation response: risk of spontaneous rescue‐free bowel movements in the short terma · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving… (2022) · Cochrane | no estimate extracted | NR | No studies |
Naloxone + oxycodone prolonged release tablets vs oxycodone prolonged‐released tablets Laxation response: risk of spontaneous rescue‐free bowel movements in the medium termb · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving… (2022) · Cochrane | no estimate extracted | NR | No studies |
Naldemedine vs placebo Laxation response: patient assessment of change in bowel status at the end of trial · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving… (2022) · Cochrane | no estimate extracted | NR | No studies |
Methylnaltrexone lower dose vs higher dose Serious adverse events · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving… (2022) · Cochrane | no estimate extracted | NR | No studies |
Low dose naldemedine vs higher doses Laxation response: risk of spontaneous rescue‐free bowel movements in the short terma · people with cancer irrespective of whether they are receiving palliative care and with opioid‐induced bowel dysfunction Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving… (2022) · Cochrane | no estimate extracted | NR | No studies |
Low dose naldemedine vs higher doses Laxation response: patient assessment of change bowel status at end of trial · people with cancer irrespective of whether they are receiving palliative care and with opioid‐induced bowel dysfunction Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving… (2022) · Cochrane | no estimate extracted | NR | No studies |
Active cycle of breathing techniques plus routine treatment vs routine treatment alone Duration of fever ‐ not reported · people with pneumonia Chest physiotherapy for pneumonia in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Active cycle of breathing techniques plus routine treatment vs routine treatment alone Duration of ICU stay ‐ not reported · people with pneumonia Chest physiotherapy for pneumonia in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Active cycle of breathing techniques plus routine treatment vs routine treatment alone Duration of mechanical ventilation ‐ not reported · people with pneumonia Chest physiotherapy for pneumonia in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Osteopathic manipulative treatment (OMT) plus routine treatment vs placebo plus routine treatment Duration of ICU stay ‐ not reported · people with pneumonia Chest physiotherapy for pneumonia in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Osteopathic manipulative treatment (OMT) plus routine treatment vs placebo plus routine treatment Duration of mechanical ventilation ‐ not reported · people with pneumonia Chest physiotherapy for pneumonia in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Positive expiratory pressure plus routine treatment vs routine treatment alone Cure rate ‐ not reported · people with pneumonia Chest physiotherapy for pneumonia in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Positive expiratory pressure plus routine treatment vs routine treatment alone Duration of total antibiotic therapy ‐ not reported · people with pneumonia Chest physiotherapy for pneumonia in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Positive expiratory pressure plus routine treatment vs routine treatment alone Duration of ICU stay ‐ not reported · people with pneumonia Chest physiotherapy for pneumonia in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Positive expiratory pressure plus routine treatment vs routine treatment alone Duration of mechanical ventilation ‐ not reported · people with pneumonia Chest physiotherapy for pneumonia in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
High‐frequency chest wall oscillation plus fibrobronchoscope alveolar lavage vs fibrobronchoscope alveolar lavage alone Cure rate ‐ not reported · people with severe pneumonia and receiving mechanical ventilation Chest physiotherapy for pneumonia in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
High‐frequency chest wall oscillation plus fibrobronchoscope alveolar lavage vs fibrobronchoscope alveolar lavage alone Duration of hospital stay ‐ not reported · people with severe pneumonia and receiving mechanical ventilation Chest physiotherapy for pneumonia in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
High‐frequency chest wall oscillation plus fibrobronchoscope alveolar lavage vs fibrobronchoscope alveolar lavage alone Duration of fever ‐ not reported · people with severe pneumonia and receiving mechanical ventilation Chest physiotherapy for pneumonia in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
High‐frequency chest wall oscillation plus fibrobronchoscope alveolar lavage vs fibrobronchoscope alveolar lavage alone Duration of total antibiotic therapy ‐ not reported · people with severe pneumonia and receiving mechanical ventilation Chest physiotherapy for pneumonia in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Conventional chest physiotherapy plus routine treatment vs routine treatment alone Duration of total antibiotic therapy ‐ not reported · people with pneumonia Chest physiotherapy for pneumonia in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Conventional chest physiotherapy plus routine treatment vs routine treatment alone Duration of ICU stay ‐ not reported · people with pneumonia Chest physiotherapy for pneumonia in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Conventional chest physiotherapy plus routine treatment vs routine treatment alone Duration of mechanical ventilation ‐ not reported · people with pneumonia Chest physiotherapy for pneumonia in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Pyronaridine‐artesunate (PY‐AS) vs other antimalarials Outcomesa,b,c · adults and children with uncomplicated malaria Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria (2022) · Cochrane | no estimate extracted | NR | No studies |
Pyronaridine‐artesunate (PY‐AS) vs artesunate‐amodiaquine (AS‐AQ) Outcomesa · adults and children with uncomplicated P falciparum malaria Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria (2022) · Cochrane | no estimate extracted | NR | No studies |
Dexamethasone vs betamethasone – maternal outcomes Death · women at risk of preterm birth Different corticosteroids and regimens for accelerating fetal lung maturation for babies at risk of preterm… (2022) · Cochrane | no estimate extracted | NR | No studies |
Dexamethasone: oral vs intramuscular – fetal/neonatal outcomes Chronic lung disease · women at risk of preterm birth Different corticosteroids and regimens for accelerating fetal lung maturation for babies at risk of preterm… (2022) · Cochrane | no estimate extracted | NR | No studies |
Betamethasone acetate plus phosphate vs betamethasone phosphate – fetal/neonatal outcomes Necrotising enterocolitis · women at risk of preterm birth Different corticosteroids and regimens for accelerating fetal lung maturation for babies at risk of preterm… (2022) · Cochrane | no estimate extracted | NR | No studies |
Betamethasone acetate plus phosphate vs betamethasone phosphate – fetal/neonatal outcomes Chronic lung disease · women at risk of preterm birth Different corticosteroids and regimens for accelerating fetal lung maturation for babies at risk of preterm… (2022) · Cochrane | no estimate extracted | NR | No studies |
Dexamethasone vs betamethasone – maternal outcomes Puerperal sepsis · women at risk of preterm birth Different corticosteroids and regimens for accelerating fetal lung maturation for babies at risk of preterm… (2022) · Cochrane | no estimate extracted | NR | No studies |
Dextromethorphan and quinidine sulfate combination (DMQ) vs placebo Quality of life · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Scopolamine (hyoscine) patches vs placebo Quality of life · people with motor neuron disease/amyotrophic lateral sclerosis with sialorrhea (excessive saliva) (all fed via… Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Radiotherapy vs botulinum toxin Reduction in the amount of saliva production in the short term using an objective measure · people with motor neuron disease/amyotrophic lateral sclerosis with excessive saliva Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Radiotherapy vs botulinum toxin Quality of life · people with motor neuron disease/amyotrophic lateral sclerosis with excessive saliva Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control Activities of daily living (primary outcome) · stroke survivors with hearing, smell, and taste perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control Quality of life and participation ‐ mobility and navigation intervention for not Pusher Syndrome (Analysis 1.2) · stroke survivors with somatosensory perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control Psychological and mental health · stroke survivors with somatosensory perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control Perception · stroke survivors with somatosensory perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control Adverse events · stroke survivors with somatosensory perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control Activities of daily living (primary outcome) · stroke survivors with tactile perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control Extended activities of daily living · stroke survivors with tactile perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control Psychological and mental health · stroke survivors with tactile perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |